STOCKWATCH: Will cancer info dump ruffle markets?
This article was originally published in Scrip
The big news at the European Cancer Congress in Amsterdam this weekend was not down to any one particular pharma company's good or bad clinical results. It was simply that all the news from the Congress was released at the same time as the organizers lifted all the embargos on presentations at the meeting. That meant that a bolus of potential market-moving and market-sensitive material was released over the weekend when no trading was taken place, rather than being staggered over the course of the Congress.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.